PepGen Inc. - 8-K Filing
PepGen reported Q1 2026 financial results with $132.3M in cash as of March 31, a net loss of $(0.26) per share ($17.8M total), and R&D expenses of $13.0M (down from $25.4M YoY). The company provided updates on its PGN-EDODM1 trial for DM1: the 5 mg/kg cohort showed favorable safety, splicing, and vHOT data; enrollment in the 10 mg/kg cohort is complete with results expected H2 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $PEPG